Persistent pricing pressure in US generics and API
Pricing pressure in US generics and API businesses persisted during the quarter, partially offset by cost efficiencies.
APLLTD / bear-case history
Track the concerns that keep returning.
Alembic Pharmaceuticals · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
India branded business underperformance
India branded business grew only 6% YoY, below market growth, and management has not provided a clear timeline for improvement beyond Q1 FY27.
Pivya launch margin drag
The branded product Pivya launch will impact near-term profitability, with management unable to quantify the margin impact.
Dependence on injectable and complex generics for future growth
Management expects injectables and complex generics to drive US growth over the next 2-3 years, but approvals and ramp-up remain uncertain.
Sustained pricing pressure in generics
Pricing pressure and competitive intensity continue to impact the US and API businesses, potentially limiting margin expansion.
US branded business margin drag
The launch of Pivya and the US branded specialty business will drag margins by 100-150 bps in the near term, with uncertain timing of breakeven.
R&D productivity and elevated spend
R&D spend increased to 11% of revenue in Q4, and guidance for FY27 is elevated at ₹750-800 crore; returns on this investment are uncertain.
New facility ramp-up delays
F2 and F3 facilities are still underutilized (40-60% on some lines), and revenue contribution from contract manufacturing may take time to materialize.